Open access · OA
via OpenAlex
Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus
Ken Fujioka, T. B. Seaton, Everton Rowe, Caitlin Jelinek, Philip Raskin, Harold E. Lebovitz, S. P. Weinstein
Diabetes Obesity and Metabolism · 2000 · ▲ 244 citations
Abstract
AIM: To determine the efficacy and tolerability of sibutramine hydrochloride in obese patients whose type 2 diabetes was poorly controlled on diet alone or with an oral antidiabetic agent. METHODS: This study was a 24-week, double-blind, multicentre trial following a 5-week placebo run-in period. One hundred and seventy-five obese (body mass index (b.m.i.) > or =27 kg/m2) patients with poorly controlled type 2 diabetes mellitus were randomized either to sibutramine (n = 89; mean age 53.5 years; mean weight 99.3 kg) or placebo (n = 86; mean age 55 years; mean weight 98.2 kg) at 16 participating centres. To achieve moderate calorie restriction (deficit > or = 250-500 kcal/day), individual dietary counselling was accompanied by either placebo or sibutramine (initial dosage of 5 mg/day titrated up by 5 mg biweekly through week 6, and maintained at 20 mg through week 24). The main outcome measures included changes in weight, b.m.i., waist and hip circumference, glycaemic control, lipid profile, and quality of life, and evaluation of reported adverse events. RESULTS: Sixty-seven per cent of sibutramine patients and 71% of placebo patients completed the study. At week 24 when comparing those who completed the course, sibutramine compared with placebo patients showed significantly greater (p < 0.001) absolute (-4.3 vs. -0.4 kg) and percentage (-4.5% vs. -0.5%) weight loss. Weight loss > or =5% or 10% was achieved by 33% and 8% of sibutramine patients, respectively, but no placebo patients (p < 0.03 or better). Improvement in glycaemic control was correlated with weight loss (p < 0.001). In 5% and 10% weight-loss responders, mean treatment differences were -0.53% and -1.65% (p < or = 0.05), respectively, for HbA1c, and -1.4 mmol/l (p < or =0.05) and -3.8 (p < or =0.05) mmol/l for fasting plasma glucose. Sibutramine patients also showed improvements in fasting insulin, triglycerides, HDL cholesterol, and quality-of-life assessments. Overall, sibutramine was well tolerated compared with the placebo. Sibutramine treatment was associated with small mean increases in blood pressure (BP) and pulse, although an increase in BP was not seen in sibutramine-treated patients who lost > or = 5% of their weight. CONCLUSIONS: Sibutramine produced statistically and clinically significant weight loss when used in combination with recommendations for moderate caloric restriction(definition). This weight loss was associated with improvements in metabolic control and quality of life, and sibutramine was generally well tolerated in obese patients with type 2 diabetes.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1046/j.1463-1326.2000.00081.x
- Canonical
- link ↗
- Fetched
- 2026-10-20 MST
Cite this
APA
Fujioka, K., Seaton, T.B., Rowe, E., Jelinek, C., Raskin, P., Lebovitz, H.E., & Weinstein, S.P. (2000). Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. <em>Diabetes Obesity and Metabolism</em>. https://doi.org/10.1046/j.1463-1326.2000.00081.x
Vancouver
Fujioka K, Seaton TB, Rowe E, Jelinek C, Raskin P, Lebovitz HE, et al. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obesity and Metabolism. 2000. doi:10.1046/j.1463-1326.2000.00081.x.
BibTeX
@article{ken2000Weight,
title = {Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus},
author = {Ken Fujioka and T. B. Seaton and Everton Rowe and Caitlin Jelinek and Philip Raskin and Harold E. Lebovitz and S. P. Weinstein},
journal = {Diabetes Obesity and Metabolism},
year = {2000},
doi = {10.1046/j.1463-1326.2000.00081.x},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Journal of Clinical Medicine 2025
Open access · CC-BY
A New Score for Metabolic Age in Type 2 Diabetes Mellitus: Physical Rating Score
Diabetes Care 2005
Open access · OA
Effect of Sibutramine on Weight Management and Metabolic Control in Type 2 Diabetes
Diabetes Obesity and Metabolism 2024
Citation only
The effects of time‐restricted eating alone or in combination with probiotic supplementation in comparison with a calorie‐restricted diet on endocrine and metabolic profiles in women with polycystic ovary syndrome: A randomized clinical trial
Nutrients 2021
Open access · CC-BY
The Effects of a Macronutrient-Based Diet and Time-Restricted Feeding (16:8) on Body Composition in Physically Active Individuals—A 14-Week Randomised Controlled Trial
JAMA Network Open 2024
Open access · CC-BY
A 5:2 Intermittent Fasting Meal Replacement Diet and Glycemic Control for Adults With Diabetes
Psychological Medicine 2015
Citation only